Code intelligence

FDA-BLA761044 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-BLA761044.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: USTEKINUMAB (USTEKINUMAB) — Type 3 - New Dosage Form

Policy FDA-BLA761044 · Rheumatology

Critical

Ustekinumab (BLA 761044), approved by Janssen Biotech as a new injectable dosage form, follows the Part B billing pathway given its injectable route of administration. As an established biologic inter

View alert

Audit documentation

Building an audit file that includes FDA-BLA761044?

The Tripwire Audit Pack exports 12 months of Rheumatology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Rheumatology audit pack — $349One-time purchase · not a subscription